These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10109799)

  • 21. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre.
    Dranitsaris G; Pilla NJ; McGreer A
    Can J Hosp Pharm; 1994 Apr; 47(2):59-64. PubMed ID: 10134128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis.
    Goetzl L; Wilkins I
    J Perinatol; 2002; 22(5):403-6. PubMed ID: 12082477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost comparison of oral, nasogastric, and intramuscular cimetidine drug delivery systems.
    Lau NC; Caldwell RD; Arford PH
    Hosp Pharm; 1992 Nov; 27(11):946-7, 950-2, 954-6 passim. PubMed ID: 10122039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefmetazole (CS-1170), a "new" cephamycin with a decade of clinical experience.
    Jones RN
    Diagn Microbiol Infect Dis; 1989; 12(5):367-79. PubMed ID: 2692950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A commentary on high-cost drugs.
    de Leon RF
    Curr Concepts Hosp Pharm Manage; 1989; 11(3):4-7. PubMed ID: 10318277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost containment through restriction of cephalosporins.
    Britton HL; Schwinghammer TL; Romano MJ
    Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining the differences among cost savings, cost avoidance, and cost reduction.
    Howard KB; Pathak DS
    Pharm Pract Manag Q; 1999 Oct; 19(3):1-7. PubMed ID: 10747680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
    von Scheele B; Peña B; Wong J; Niculescu L
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii53-9. PubMed ID: 14585918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABC inventory analysis and economic order quantity concept in hospital pharmacy purchasing.
    Ballentine R; Ravin RL; Gilbert JR
    Am J Hosp Pharm; 1976 Jun; 33(6):552-5. PubMed ID: 1274974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of clinical pharmacists to cefazolin utilization.
    Witte KW; Hatoum HT; Hoon TJ
    Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing high cost and biotech drugs: two institutions' perspectives.
    Dana WJ; McWhinney B
    Hosp Formul; 1994 Sep; 29(9):638-45. PubMed ID: 10137060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative evaluation of safety and efficacy of cefmetazole and cefoxitin in lower respiratory tract infections.
    Yangco BG; Kenyon VS; Halkias KD; Toney JF; Chmel H
    J Antimicrob Chemother; 1989 Apr; 23 Suppl D():39-46. PubMed ID: 2656626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing and implementing guidelines to promote appropriate use of fluconazole therapy in an AIDS clinic.
    Anassi EO; Egbunike IG; Akpaffiong MJ; Ike EN; Cate TR
    Hosp Pharm; 1994 Jun; 29(6):576-8, 581-2, 585-6. PubMed ID: 10134178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of pharmacy personnel to positively impact hospital finances.
    Hutchinson RA; Hatoum HT; Kolinski R; Riley DW
    Hosp Formul; 1989 Aug; 24(8):450, 453. PubMed ID: 10294357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions.
    Pearson VE; King LM
    Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.